FTC urges top PBMs to outline effects on drug pricing, pharmacies

The FTC is requesting large, vertically-integrated players in the pharmacy benefit management industry share insights on their influence over drug pricing and access. 

The request for information follows a previous public inquiry on PBMs, which revealed that independent pharmacies found contracts with PBMs to be confusing and predatory. 

The request targets payers with vertically-integrated PBMs, including UnitedHealth Group's OptumRx, Cigna's Express Scripts and CVS Health's Caremark. 

The public comment period extends through April 25.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Top 40 articles from the past 6 months